Stocks to Buy: 95% Return Is Just the Start For This Biotech Play

Investors looking for stocks to buy in 2014 have had an abundance of new options as 94 companies have gone public this year, according to Renaissance Capital.

The average return for those 94 companies since their IPO date is 9%. But some stocks have far outpaced the average and are still at great buy-in points, even after huge gains.

stocks to buyMoney Morning's Defense & Tech Specialist Michael A. Robinson has been following the best biotech IPOs of 2014. Among them he found a stock that still provides investors a great profit opportunity, even after posting a 95% return since its IPO date.

"As impressive as this stock has been, the market hasn't quite figured out just how profitable it'll be," Robinson said.

The stock is Auspex Pharmaceuticals Inc. (Nasdaq: ASPX), a biopharmaceutical company that develops treatments for very rare diseases.

Since it went public on Feb. 4, ASPX stock has gained an impressive 95%, including a 31% gain on its first day of trading. That compares to a 7% gain for the S&P 500 and a 2% gain for the Nasdaq during that period.

Meanwhile, the biotech sector has faltered. The iShares Nasdaq Biotechnology Index ETF (Nasdaq: IBB), which tracks biotech stocks, has dropped 6%. ASPX hasn't just avoided the sector's plunge; its share price has almost doubled in the same time.

And according to Robinson, ASPX stock still has room to run. Here's why...

Why Auspex Pharmaceuticals (Nasdaq: ASPX) Is on Our "Stocks to Buy" List

San Diego-based Auspex Pharmaceuticals primarily develops drugs that treat incredibly rare diseases, known as "orphan drugs" - and they are huge revenue generators in the biotech field.

Orphan drugs treat diseases that affect fewer than 200,000 people in the United States. Because the diseases are so rare, the orphan drugs developed to treat them are given a seven-year patent. That compares to the typical five-year patents all other drugs receive in the United States.

These drugs can also be incredibly expensive, with many costing more than $200,000 per year. The most world's most expensive drug, Soliris, costs approximately $440,000 per person, per year.

That's how companies that make orphan drugs post such massive revenue numbers. Orphan drug maker Alexion Pharmaceuticals Inc. (Nasdaq: ALXN) expects to generate approximately $2 billion in 2014 from its drug Soliris alone. Celgene Corp. (Nasdaq: CELG) made $1.14 billion off its orphan drug Revlimid in the just the fourth quarter of 2013.

Auspex focuses on conditions that cause hyperkinetic movement disorders, like Huntington's disease and Tourette's syndrome. ASPX currently is developing a drug called SD-809, which is designed to treat involuntary abdominal spasms related to Huntington's. That's a hereditary neurodegenerative disease that results in motor, cognitive, and psychiatric disability, primarily due to the destruction of neurons in the brain.

"SD-809 is in advanced clinical trials and has already shown a tremendous amount of potential,"

Robinson said. "Other drugs in Auspex's pipeline include those used to treat rheumatoid arthritis and conditions like pulmonary fibrosis (scarring of the lungs) and obstruction of the coronary arteries."

In the last year, ASPX did not generate any revenue, but that could change quickly if SD-809 is approved soon. Bringing orphan drugs to market is a huge revenue generator for biotech companies, and the seven-year patents these drugs are given ensure market exclusivity.

ASPX had an offer price of $12 when it went public back in February. Today, the stock opened at $23.39. While it's nearly doubled since going public, look for ASPX stock to soar higher as SD-809 progresses through clinical trials.

Do you invest in the biotech field? Which pharmaceutical companies do you think are buys right now? Join the conversation on Twitter @moneymorning using #Biotech.

If you've been counting on your pension, you may want to revise those plans, as most are way underfunded. Now is the time to act, because your pension funds are drying up...